首页> 中文期刊> 《海南医科大学学报(英文版)》 >Effects of entecavir on platelet function, PTA and HBV-DNA levels in patients with hepatitis B cirrhosis

Effects of entecavir on platelet function, PTA and HBV-DNA levels in patients with hepatitis B cirrhosis

         

摘要

Objective: To explore the effect of entecavir on platelet function, PTA and HBV-DNA levels in patients with hepatitis B cirrhosis. Methods: A total of 132 patients with hepatitis B cirrhosis admitted in our hospital from September 2012 to May 2016 were randomly divided into control group (n=66) and observation group (n=66). The two groups were treated with routine treatment, such as reducing enzyme activity and protecting liver function. The control group was treated with lamivudine on the basis of routine treatment and the observation group was treated with entecavir. The changes of liver function, liver fibrosis, platelet index, PTA and HBV-DNA expression level in the two groups were compared. Results: Before treatment, there was no significant difference between alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), type III procollagen (PC III), laminin (LN), type IV collagen (IV-C), hyaluronidase (HA), platelet count (PLT), platelet distribution width (PDW), mean platelet volume (MPV), prothrombin activity (PTA) and hepatitis B virus RNA (HBV-DNA). After treatment, ALT, AST, TBIL, PC III, IV-C, LN and HA in both groups were significantly decreased than those before the treatment, and the decrease of PC III, IV -C, LN and HA in observation group was more significant than that of the control group; PLT and PTA in both groups were significantly increased than before treatment, while MPV, PDW and HBV-DNA were obviously decreased than before treatment, and PLT and PTA in the observation group were remarkably increased than control group, while MPV, PDW, and the control group were significantly lower than those in the control group. Conclusions: Entecavir in the treatment of hepatitis B liver cirrhosis, can reduce the HBV-DNA level, and then obviously enhance the liver function, inhibit the development of liver fibrosis, correct the abnormal platelet parameters and improve coagulation function.

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2018年第17期|27-30|共4页
  • 作者单位

    Infection Department, Anqing No.1 people's Hospital, Anqing 246000, Anhui, China;

    Infection Department, Anqing No.1 people's Hospital, Anqing 246000, Anhui, China;

    Infection Department, Anqing No.1 people's Hospital, Anqing 246000, Anhui, China;

    Infection Department, Anqing No.1 people's Hospital, Anqing 246000, Anhui, China;

    Infection Department, Anqing No.1 people's Hospital, Anqing 246000, Anhui, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号